Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abandon, afforded, avoid, buy, Certificate, confidence, consolidated, consummated, corrected, costly, decision, demonstrated, detected, DGCL, diminished, dissolution, dissolved, eliminate, encountered, eventually, exit, fact, firm, fractional, freely, Gaither, impossible, improvement, indemnification, Ineffective, inhibit, intestate, lack, lead, leading, maximize, misstatement, necessity, notwithstanding, pro, proceed, promptly, protracted, proxy, rata, reaction, release, remediate, resolve, revocation, Secretary, segregation, thereunder, therewith, threatened, timeframe, unanimously, unanticipated, unmatured, voluntary, wind, winding
Filing tables
Filing exhibits
NEXI similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NexImmune, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge that:
The Quarterly Report for the period ended September 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 17, 2023 | By: | /s/ Kristi Jones | ||||||
Kristi Jones | ||||||||
Chief Executive Officer (Principal Executive Officer) |